HomeCompareHUMDF vs NNN

HUMDF vs NNN: Dividend Comparison 2026

HUMDF yields 484.14% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47899.99M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — HUMDF vs NNN

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HUMDF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, HUMDF beats the other by $28,951,553,010.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + NNN for your $10,000?

HUMDF: 50%NNN: 50%
100% NNN50/50100% HUMDF
Portfolio after 10yr
$23950.02M
Annual income
$17,030,327,923.14/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
NNN buys
0
No recent congressional trades found for HUMDF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFNNN
Forward yield484.14%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$47900.01M$25.5K
Annual income after 10y$34,060,653,223.60$2,622.67
Total dividends collected$46687.76M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HUMDF vs NNN ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$59,114$48,414.43$10,735$614.96+$48.4KHUMDF
2$330,728$267,475.81$11,572$708.43+$319.2KHUMDF
3$1,752,431$1,398,551.73$12,531$819.53+$1.74MHUMDF
4$8,800,812$6,925,711.29$13,633$952.29+$8.79MHUMDF
5$41,922,789$32,505,919.38$14,909$1,111.84+$41.91MHUMDF
6$189,569,894$144,712,509.91$16,392$1,304.77+$189.55MHUMDF
7$814,403,207$611,563,420.90$18,129$1,539.52+$814.39MHUMDF
8$3,326,842,984$2,455,431,552.18$20,173$1,827.08+$3326.82MHUMDF
9$12,933,979,587$9,374,257,594.32$22,597$2,181.81+$12933.96MHUMDF
10$47,900,011,382$34,060,653,223.60$25,491$2,622.67+$47899.99MHUMDF

HUMDF vs NNN: Complete Analysis 2026

HUMDFStock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this HUMDF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs OHUMDF vs KOHUMDF vs MAINHUMDF vs ADCHUMDF vs EPRTHUMDF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.